Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS
Retrieved on:
Friday, December 8, 2023
Woman, Safety, Therapy, Ottawa Hospital Research Institute, Intensity, Podium, Breast cancer, Fatigue, Patient, Gene expression profiling, Necrosis, The Ottawa Hospital, T helper cell, Immunotherapy, Breast, CD4, Gene expression, Biomarker, Mastectomy, MD, Nausea, Diagnosis, Cancer, University, Downregulation and upregulation, Neoplasm, News, Publication, Injection, NK, Vaccine, Medical imaging
"A large unmet need in the treatment of breast cancer is that the majority of breast cancers are immune quiescent; resulting in minimal response to immunotherapies.
Key Points:
- "A large unmet need in the treatment of breast cancer is that the majority of breast cancers are immune quiescent; resulting in minimal response to immunotherapies.
- A functional pathway enrichment analysis was conducted and confirmed positive changes in T-cell activation, lymphocyte activation and inflammatory response.
- Over 95% of treatment-emergent adverse events (TEAEs) were low grade 1 or 2 primarily localized pain, fatigue, and nausea.
- We see the potential opportunity for our technology and drug products in both the metastatic and presurgical settings for many types of cancers."